Effect of macaúba Oil Combined With Green Exercises

Condition(s) studied

Investigational drug(s) / intervention(s)

Macauba oil: Macauba oil will be encapsulated in the form of a food supplement.

Placebo: Placebo capsules containing mineral oil.

Daytime Green Exercise: Participants will perform supervised moderate-intensity exercise outdoors in a green environment during the daytime.

Nighttime Green Exercise: Participants will perform supervised moderate-intensity exercise outdoors in a green environment during the nighttime.

Study summary

Animal model studies involving macaúba oil demonstrate beneficial effects on fat, oxidative stress, and adipogenesis. This study aims to evaluate lipid oxidation and mental stress levels in trained individuals following macaúba oil supplementation combined with outdoor exercise (green exercise) performed in a fasted state. The study will be randomized, double-blind, and placebo-controlled. Participants will receive either 400 mg of macaúba oil or placebo pills over an 8-week period while engaging in 5 km running sessions four times a week. Assessments of anthropometric parameters, body composition (DEXA), biochemical parameters, and heart rate will be conducted before and after the intervention, alongside the administration of a questionnaire regarding emotional well-being and perceived stress. At the end of the intervention, results will be analyzed using Kubios HRV 2.0 and GraphPad Prism (version 5.0) software; the Kolmogorov-Smirnov and Shapiro-Wilk tests will be applied to verify data normality, the Student's t-test for parametric data, and the Kruskal-Wallis and Wilcoxon-Mann-Whitney tests for non-parametric data.

Eligibility

Primary outcome measure(s)

• Fasting plasma glucose concentration (mg/dL) — Baseline and Week 8
  Plasma glucose concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
• Percentage of glycated hemoglobin (HbA1c) (%) — Baseline and Week 8
  Glycosylated hemoglobin (HbA1c) (%) will be measured in whole blood.
• Plasma concentrations of LDL cholesterol, HDL cholesterol, VLDL cholesterol, and total cholesterol (mg/dL) — Baseline and Week 8
  Plasma low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol and total cholesterol concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
• Plasma triglyceride concentration (mg/dL) — Baseline and Week 8
  Plasma triglyceride concentration (mg/dL) will be measured using an enzymatic colorimetric assay.
• Plasma malondialdehyde (MDA) concentration (nmol/mL) — Baseline and Week 8
  Plasma malondialdehyde (MDA) concentration (nmol/mL) will be measured as a biomarker of lipid peroxidation.
• Erythrocyte glutathione peroxidase activity (U/g Hb) — Baseline and Week 8
  Erythrocyte glutathione peroxidase activity (U/g Hb) will be measured as a biomarker of antioxidant defense.
• Erythrocyte glutathione reductase activity (U/g Hb) — Baseline and Week 8
  Erythrocyte glutathione reductase activity (U/g Hb) will be measured as a biomarker of antioxidant defense.
• Plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) activities (U/L) — Baseline and Week 8
  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Gamma-glutamyl transferase (GGT) (U/L) will be measured on plasma as an indicator of liver function.

Trial sites (2)

More Federal University of Minas Gerais trials in Brazil

Other trials for the same condition